A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: Medivation, Inc.
• Treatments: Alprazolam

Criteria

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 18 and 55 years.

• Recreational polydrug user with a history of CNS depressant use.

Exclusion Criteria:

• History of clinically significant neurologic condition(s), such as seizures, convulsions, epilepsy, or significant head injury, as judged by the investigator or designee.

• A known history of hypersensitivity or previous intolerance to dimebon or other antihistamines.

• Self-reported history of drug or alcohol dependence (except nicotine or caffeine) in the 2 years prior to screening, or drug or alcohol dependence as defined by the (DSM-IV-TR) in 12 months prior to screening, including subjects who have ever been in a substance rehabilitation program (other than treatment for smoking cessation).

• History of clinically significant psychiatric disorder(s), as judged by the investigator or qualified designee.